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Research into the identification and use of protein biomarkers for use in veterinary clinical
pathology has produced numerous potential analytes that could become common tests
in the future. One problem that has to be overcome in the general acceptance of a
novel biomarker is that differing standards for calibration may be developed by individual
laboratories or the diagnostic companies that will provide kits for widespread use. This
has been apparent in the development of acute phase protein biomarkers such as canine
C-reactive protein. In order to overcome this problem an international initiative is required
to ensure that assays developed in separate laboratories would have a consistent
calibration protocol so that results produced are equivalent. International reference
preparations for serum protein analysis for each relevant species should be established
for use as primary standard in the calibration of biomarkers for veterinary diagnosis.
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INTRODUCTION
Biomarkers are defined by the Biomarker Working Group of the National Institutes of Health
Director’s Initiative on Biomarkers and Surrogate Endpoints as “A characteristic that is objectively
measured and evaluated as an indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention” (1). This covers many if not all analytes
in diagnostic laboratories, however in veterinary clinical pathology, the major recent biomarker
developments which have been valuable for improving the diagnosis of disease in domestic animals
have been in the identification, validation and assay development for protein biomarkers especially
in serum, or plasma.
Over the last few decades, there have been investigations into a number of protein biomarkers
the concentration of which have the potential for use in diagnostic laboratories and potentially
for point-of-care testing in veterinary practices. Thus, proteins such as, C-reactive protein, serum
amyloid A, α1 acid glycoprotein, adipokines, cytokines, telomerase, paroxonase, pancreatic lipase,
GLUT1, cardiac troponin, brain natriuretic peptide, VCAM-1 and LCAM1 are already in use or
their potential has been identified for monitoring a wide variety of conditions including innate
immunity, neoplastic disease and cardiac medicine in both companion and production animals.
Tremendous strides have been made in the discovery and application of veterinary biomarkers and
these have been reviewed elsewhere (2–4).
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However, there is a major hurdle to overcome in the
implementation of novel biomarkers for veterinary diagnosis,
especially for methods that could be implemented around the
world. There is no international agreement for harmonization
of assay calibration for veterinary biomarkers. This means that
there is no accepted means to calibrate a specific assay for a novel
biomarker. Therefore, a potential problem can arise in provision
of consistent results and alignment of clinical interpretation,
especially if two or more laboratories use differing calibration
standards. If a globally agreed protocol can be developed to
overcome this shortcoming in veterinary clinical pathology,
then all laboratories and of equal importance all diagnostic kit
manufacturers would have access to the same accepted standard
material for calibration so that results would then be comparable
between methods.
Before outlining a solution to this problem it is instructive to
illustrate the means whereby biomarkers have been developed
in the recent past. For example, following the development of
assays for canine C-reactive protein (cCRP) over the last 40
years illustrates how problems can arise. Current technological
approaches can accelerate the discovery of further biomarkers
and integral to further advances would be a regulatory system
for international harmonization of the standards used in assay
calibration. It is also instructive to illustrate how standards for
calibration have been developed for clinical biochemistry in
human medicine.
BIOMARKER DEVELOPMENT
The incentive to establish a novel biomarker has varied origins. It
may be by a deliberate investigation to identify a biomarker for a
specific disease, it may be a serendipitous discovery of a protein
that can be the target for a new biomarker test, or it may be by
comparison to established biomarkers in humanmedicine. It was
the latter that formed the basis for the development of cCRP as
a marker of inflammation, infection and trauma. Identified as a
serum protein in the 1920’s the use of this biomarker in human
medicine was established in the 1970s and today is one of the
most frequently assayed analytes in medical hospitals and general
practice. Although CRP had been identified in canine serum
during an acute phase response (5) its use as a biomarker in
veterinary medicine was not documented until assay methods for
use in diagnostic laboratories were established independently in
Japan and UK (6, 7). A variety of immunoassay formats including
radial immunodiffusion, ELISA and immunoturbidimetry were
established in veterinary research laboratories. Unfortunately, at
this early stage a common calibration standard was not developed
in the active research laboratories. However, the clinical utility
of the use of cCRP as a marker for disease in dogs developed
because in-house assays used in research studies were able to
identify the best applications (8) of this acute phase protein
test. The tests for cCRP, as it is elevated by many causes, were
found to be especially valuable in identification of infectious
and inflammatory disease, with quantification being important
to reveal the extent of pathology and to monitor responses
to treatment (9).
Encouraged by the initial findings and by a growing network
of specialist centers the clinical uses of the test became established
with major application by laboratories such as in Murcia (10),
Copenhagen (11), in Europe and Hokkaido in Japan (6). Outside
the main research laboratories further use of cCRP was enabled
by the finding that some but not all assay kits for human
CRP could be used to measure the canine protein (12). At an
earlier stage in Japan than in Europe, commercially produced
kits for determining cCRP concentrations in serum or plasma
were developed which led to a widespread uptake of cCRP
analysis in veterinary practices in Japan. Now a number of cCRP
assay kits both for laboratory analysis and for point-of-care
use have been developed by differing manufacturers in Europe
and the USA.
The more ready access now available by veterinarians in
practice to cCRP assays has led to a virtuous cycle in that
the greater availability is leading to more research and more
defined applications. Indeed the full extent of the uses of cCRP
as a marker of innate immunity in dogs is probably not fully
exploited and will benefit from multi-centric determination
of benefits and limitations. This is highlighting that it is
essential for comparison between research results from different
laboratories that a common basis is used for calibration of
cCRP assays. Then reference ranges, clinical decision point
and clinical findings will be similar whichever diagnostic kit
is utilized in a clinical biochemistry laboratory or in practice
point-of-care instrument.
The development, validation and use of cCRP has therefore
been a 30 year process. Current develops in the discovery of novel
biomarkers has been accelerating, but for implementation of
other new tests will face similar barriers as have been encountered
for cCRP. Thus, it is opportune to develop a process that would
be applicable to all new assays for veterinary biomarkers, not only
for biomarkers in serum but also with the exciting prospects for
monitoring disease with non-invasive samples for instance by use
of biofluids such as saliva (13–15), or milk (16, 17) as the matrix
for examination.
A major driver to the discovery of new veterinary biomarkers
is the application of recent advances in proteomics using liquid
chromatography and mass spectrometry (18) so making it more
imperative that a process is developed to deal with calibration
standardization. In relevant example in dogs, such advanced
technology has identified biomarkers associated with canine
babesiosis (19) while in another study biomarkers for treatment
monitoring of canine leishmaniosis (20) have been discovered.
Feline biomarkers have also been investigated by proteomic
study in research on familial hypertrophic cardiomyopathy (21).
In farm animal medicine the use of proteomics has generated
substantial interest in biomarker development, especially for
disease such as bovine mastitis where an on-farm biomarker test
could be particularly valuable (22). For global utilization of such
advances, harmonization of assay calibration will be important, if
not essential.
CALIBRATION FOR REFERENCE
STANDARDS FOR PROTEIN BIOMARKERS
For the majority of assays currently employed in veterinary
clinical biochemistry, their calibration is well-established. For
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small molecules such as ions, metabolites such as urea and
glucose and steroid hormones, the molecules are identical across
species. For enzymes such as alkaline phosphatase their activity
is measured by the same enzyme reactions in all species so that
calibration does not present a problem. Similarly albumin and
total protein are measured by chemical reactions common in all
species and their calibration is well-established.
Specific protein biomarkers present a different problem as the
proteins often vary across different species due to differences
in their genome and protein conformation. Furthermore,
differences in the matrix of the sample between species may,
interacting with species specific protein, cause differences
in the calibration of assays. Therefore, when measured by
immunoassay, themethod of choice formost protein biomarkers,
antibody reactions will differ between species and there is
also variation between the reactions of antibody from differing
sources. Furthermore, a gold standard calibrator of a pure
sample of the protein biomarker may only be available by
tedious purification procedures which commonly do not yield
preparations of 100% purity. Recombinant protein or synthesized
peptides can be used for production of calibration standards
either polyclonal or monoclonal antibody and calibration
standards can be based such synthesized protein but they may
not react as native protein. For instance glycosylation may be
absent in synthesized protein or the native conformationmay not
be achieved reducing antibody interaction. These features mean
that assays based on purified protein or recombinant protein
may give different calibrations when used in immunoassay
standard curves. A freely available calibration standard for
use in assay development would overcome these hurdles to
biomarker development.
The problem that can arise from the lack of an internationally
recognized primary calibration standard preparation can be
illustrated by the study conducted by Munoz-Prieto et al. (12)
in which canine serum with differing concentrations of cCRP
were used as quality controls (QC) to determine the precision of
four different commercially available assays for this biomarker.
In assessment of the interassay coefficient of variance (CV) the
high level QC sample gave acceptable CV values for all four assays
of < 12.86% but the mean ± SD values varied by 50% ranging
from 97 ± 12 mg/L to 150.8 ± 14.3 mg/L1. For the medium
level QC sample CVs were all <11% but the mean values varied
by 240% ranging from 28.7 ± 3.1 to 70.4 ± 12.5 mg/L. For the
low QC all the CVs were <15% but the mean values varied by
383% ranging from 3.18± 0.19 mg/L to 12.2± 1.28 mg/L on the
same QC sample. Canine CRP reference ranges based on samples
from healthy dogs in the same region (∼10 mg/L) as the lowest
of these QC samples (7, 23). A difference of approaching 400%
between assays is not ideal and could lead to false negative or false
positive results if a range from one assay were to be used for result
interpretation from another cCRP assay method.
There have been few if any similar investigations comparing
assays for other novel protein biomarkers, however there
has been recent studies of results from assays of bovine
haptoglobin in investigation of bovine respiratory disease that
1Units are used as in the papers quoted.
illustrate the problem caused by lack of an international
calibration standard. A meta analysis of papers in the literature
reporting on the use of bovine haptoglobin as a biomarker
of this condition (24) identified 314 studies although only
23 met inclusion criteria for the meta analysis. Of these
52% of the investigations used an ELISA method from one
manufacturer with a consistent calibration standard which gave
reference range in healthy cattle of 0–0.15 mg/ml1 with a
median haptoglobin concentration of 2.6 mg/ml in cattle with
bovine respiratory disease (25). In contrast another recent
investigation (26) using an ELISA from a different manufacturer
described the serum concentration of haptoglobin in healthy
cows as being <10 ng/ml1 with serum concentrations 115–
163 ng/ml in animals with bovine respiratory disease thus
showing a 104 difference in the reported values in the
disease cases between results obtained by different commercially
available assays. It is important that such variations are
eliminated especially future development of novel protein
biomarkers as they transfer from research laboratories to use in
clinical assessment.
Similar problems have been encountered and overcome
by scientists in human clinical biochemistry. Solutions have
been applied by international agreement to the benefit of the
diagnostic industry so that whichevermethod andmanufacturer’s
product is used, specific protein assay kits are calibrated against a
common standard which is openly available to any producer with
the result that all assays for a particular serum biomarker should
give a similar result.
Collaborative initiatives under the auspices of the
International Federation of Clinical Chemistry (IFCC) set a
precedent that has been in place for over three decades. In 1994
the IFCC established an international Reference Preparation for
Proteins in Human Serum (RPPHS) (27, 28) which provided
a pool of human serum with a known concentration of the
major biomarkers in the serum determined as the mean
value of all laboratories in the collaboration. This has been
updated with the most recent version being ERM-DA470k
(29, 30). In veterinary science, there was an initiative to
generate similar reference preparations for calibration of acute
phase protein in bovine and porcine serum (31) and these
are still available from the University of Copenhagen and
University of Zaragosa, respectively. Although these reference
preparations have been available knowledge of their existence
was not widely disseminated and in future it will be important
that all potential users should be aware of the availability of
such preparations.
However, not all protein assays for use in veterinary clinical
pathology present a problem in calibration. For instance, assays
for canine troponin I (cTnI) the cardiac biomarker, are often
based on antibodies produced against the human cTNI protein
but the high degree of conservation of cTnI in structure across
species (32) enables the use of these assays in canine cardiac
cases with calibration against the human protein. Such assay
development where the human calibrant is well-established and
validated or where there is agreement among diagnostic kit
manufacturers on the nature of the calibrator, would not need
further attention.
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TABLE 1 | A protocol for preparation and standardization of biomarker calibrators.
1. Prepare a pool of serum suitable for the programme.
2. Dispatch aliquots to laboratories where the protein biomarker assays are in use.
3. Each laboratories will analyse serum for the biomarkers of choice.
4. Results will be returned to a central data analyst at the coordinating laboratory with details of the assay method and kit manufacturer.
5. The all laboratory mean for each protein biomarker in the serum will be determined.
6. After agreement on the mean value of each protein biomarker the pooled serum will be used as a primary calibrator of all assays.
7. The pooled serum will be stored securely at 3 locations at −80◦C in aliquots and made available to any laboratory and diagnostic manufacturer for use as
a laboratory primary standard against which working standards can be calibrated.
TABLE 2 | A proposal for an international working party for standarization of calibration of veterinary biomarkers.
Formation of the working party
1. Members delegated from ISACP, JSVCP, ESVCP, ASVCP, and other national associations in order to relate discussion to their members.
2. Members from industry to liaise with all veterinary biomarker companies.
3. Experts appointed in protein biomarker analysis, including scientific (protein biochemistry, molecular biology), in veterinary clinical pathology and in
statistical analysis.
Initial activity of the working party
4. Identify biomarkers where standards are required.
5. Define standard operating procedures for preparation analysis and distribution of international reference material for veterinary biomarker assays.
6. Identify participating laboratories and a coordinating center.
7. Seek funding from industry and academia—including experts in metrology, Institute for Reference Material and Measurements for production of European
Reference Material, Institute for Biological Standards.
A PROPOSAL FOR INTERNATIONAL
HARMONIZATION OF VETERINARY
BIOMARKER CALIBRATION
Procedures for developing these reference preparations for
assays, where they are needed, are described in Table 1 and
involves the following protocol for calibrators for assays for a
specific species. A pool of serum of the species should be prepared
containing the analyte being measured at a concentration
aligning with the upper region of standard curves in use. The pool
would be made by or transferred to the coordinating laboratory.
Aliquots would be distributed to laboratories where the relevant
protein biomarker assays are in use and the laboratories will
analyse serum for the biomarkers of choice. Results will be
returned to a central data analyst at the coordinating laboratory
with details of the assay method and kit manufacturer. An
all laboratory mean for each protein in the serum will be
calculated and all partners in association with the scheme will
reach agreement on the mean value of the protein biomarker
which will then be used as primary standard for calibration of
assays and diagnostic kits. A stock of the standard will be stored
securely at −80◦C in at least 3 locations and in aliquots that
can be distributed on request to any laboratory and diagnostic
manufacturer for use as a laboratory primary standard against
which working standards can be calibrated.
The current climate for developing veterinary biomarkers
with increased recognition of their potential value in diagnosis,
and the increasing involvement of commercial organizations
developing diagnostic testing for the global community, make
this an opportune time for there to be an international initiative
for addressing the problem of a lack of veterinary reference
preparations for animal species. The requirement for species
specific reference preparations but would in the first instance
focus on canine and feline serum proteins to supplement the
previous development of bovine and porcine serum preparations.
The International Society of Animal Clinical Pathology
(ISACP), as a society with international reach has agreed to
sponsor this process by initiating a working group to define a
clear plan of how this can be facilitated. The working group
would be composed of veterinary academic and diagnostic
industry representatives including representatives from national
and supra-national organizations in the field, such as the
American College of Veterinary Clinical Pathology, the Japanese
College of Veterinary Clinical Pathology, the European College
of Veterinary Clinical Pathology and other related organizations.
The Working Party would be charged with the responsibility to
prepare a detailed plan for establishing International Veterinary
Biomarker Reference Preparations. An outline of the Working
Party proposal is given in Table 2 and consists of the following.
The Working Party should have members from the major
national/regional societies where these exist covering veterinary
clinical pathology in North America, Japan and Europe and
also from national groups where such societies are not present.
There should be members from diagnostic companies involved
in the preparation of veterinary biomarker diagnostic kits.
There should also members who have the technical skill and
experience to oversee the preparation, distribution and analysis
of results from calibrator standardization. The working party
should develop a standard operating procedure to be used in
preparing an international reference preparation for each of the
major veterinary species. Laboratories capable of participating
in the development of the calibrators will be identified and a
Frontiers in Veterinary Science | www.frontiersin.org 4 July 2019 | Volume 6 | Article 210
Eckersall Calibration of Biomarker Assays
coordinator of the process confirmed. Funding will be required
to undertake this programme and could be sought from industry,
who will benefit directly from having consistent and recognized
biomarker calibration, academia via grant application to national
and international funding agencies and societies devoted to
improving animal health and welfare.
CONCLUSION
The development and widespread use of veterinary protein
biomarkers is increasing but for regular use by diagnostic
laboratories across the world it is important that methods use
common reference preparations for calibration of standards
and generation of standard curves for quantification of
the biomarkers in clinical samples. In order to enable the
development of species specific reference preparations an
international harmonization programme is proposed that will
allow assays to be developed to a global calibration level so that
there should be comparable results obtained from investigation
of a similar sample whichever assay method or diagnostic
kit is used. The nature and extent of such a programme is
open for debate among clinical pathologists in research, clinical
laboratories and industry with the ultimate aim of improving and
harmonizing biomarker assays for veterinary diagnosis.
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